As a leader and expert in the field of psychotropic drug development, Creative Biolabs provides state-of-art technologies to meet any requirement of our customers. We have completed a series of challenges in the past years. In particular, we have established an advanced selective serotonin reuptake inhibitors (SSRIs) discovery platform which enables us to offer a series of high-quality services for treating a full range of psychiatric disorders.
Introduction to Selective Serotonin Reuptake Inhibitors
SSRIs have been considered as effective drugs for the treatment of psychiatric diseases, such as post-traumatic stress disorder (PTSD), obsessive-compulsive disorder (OCD), depressive illness, anxiety, panic disorder, as well as obsessive-compulsive disease (OCD). Pilot studies have demonstrated that SSRIs can strongly inhibit the absorption of noradrenaline (NA) or/and 5-hydroxytryptamine (5-HT) by using specific neurotransmitter receptors and enzymes. Moreover, a series of SSRIs characterization assays, such as the selectivity, toxicity, in vivo studies, and pharmacological testing, have been generated for evaluating the effectiveness of SSRIs in pre-clinical trials. The results have indicated that SSRIs are relatively safe and have few side effects compared with other antidepressants. As a result, a wide variety of SSRIs, including citalopram, fluvoxamine, sertraline, fluoxetine, and escitalopram, have been developed and broadly used in many clinical therapies.
SSRIs Discovery Services for Psychiatric Diseases
In the past few years of studies, abnormal levels of monoamine in the synapse have been associated with a wide battery of psychiatric disorders, such as depressive illness, anxiety disorders, compulsivity, premenstrual dysphoric disorder (PMDD), and bulimia. Meanwhile, many reports have shown that SSRIs can block serotonin, thereby increasing 5-HT transmission. Furthermore, recent studies have suggested that the high level of serotonin can activate all 14 serotonin receptors, the safety of SSRIs needs to be further analyzed.
Currently, Creative Biolabs offers a wide collection of SSRI discovery and assessment services to help develop more effective SSRIs and improve their efficacy in different psychiatric disease models. For example, we have established in silico approaches to discover novel SSRIs based on chemical databases. In general, the candidate target will be scored by 3D virtual screening models. The potential hits derived from databases will be further analyzed by our ADMET models, and their binding stabilities will be finally tested. Based on our platform, several compounds have been confirmed that can be used as potential targets for new SSRIs discovery.
Why Creative Biolabs?
In addition to providing information on target identification, SSRIs design, and the most important psychiatric disease models of candidate drugs, Creative Biolabs can also tailor our services to the specific requirements of our customers. If you have already performed a part of the computing procedures in your lab, we can also integrate comprehensive pre-clinical studies into your workflow.
-
3D profiles for target identification
-
Multiple chemical databases
-
Professional knowledge of SSRIs design
-
Integrated solution based on various assays
Creative Biolabs is recognized as the world leader for providing the most diverse portfolio of psychotropic drug development solutions for worldwide customers. We are always committed to assisting our clients with the most satisfactory SSRIs-based services. If you are interested in our services, please contact us for closer communication to learn how we can be involved in your project. Separate services or integrated end-to-end solutions are all welcomed.
For Research Use Only.
